Abstract
Purpose :
To evaluate the effects of autologous platelet rich plasma (PRP) eye drops in the treatment of moderate to severe dry eye patients with primary and secondary Sjögren's syndrome (SS) who were dissatissfied with other dry eye therapies.
Methods :
This retrospective case series enrolled individuals diagnosed with both primary and secondary Sjogren’s syndrome. A total of 12 patients (8 with primary SS and 4 with secondary SS), underwent treatment with autologous platelet rich plasma (PRP) eye drops over a 3-month period at a singular outpatient clinic in Vancouver, Canada. Participants were concurrently undergoing various other dry eye therapies to manage their symptoms, but were still dissatisfied and PRP was introduced to provide further management. Patients were instructed to administer the drops four times daily for 3-months. Assessments, including the Canadian Dry Eye Assessment (CDEA) questionnaire score, Patient Subjective Assessment (PSA) score, corneal staining (CS), and conjunctival staining (CS), were conducted both pre and post PRP treatment.
Results :
Significant improvements in dry eye symptoms and corneal staining was noted. Improvement in conjunctival staining was also observed. Subjective CDEA composite scores significantly improved over 3 months. (Baseline CDEA mean 32.3 SD 7.30, 3 months mean 13.2 SD 9.4; p=.000007) PSA scores also improved (Baseline PSA mean 9.9 SD 4.72, 3 months mean 5.1 SD 1.37; p=.0063). There was an improvement in corneal and conjunctival staining. (Baseline Corneal staining mean 2.9 SD 1.59, 3 months mean 1 SD 0.66; p=.0027). (Baseline Conjunctival staining
Conclusions :
In this retrospective case series, the signs and symptoms of dry eye in patients with primary and secondary Sjogren’s were significantly reduced after treatment with PRP eye drops. Sjogren’s syndrome patients may stand to benefit from the addition of PRP drops to their other dry eye treatments.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.